Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Trial Profile

A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafasitamab (Primary) ; Idelalisib; Venetoclax
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms COSMOS
  • Sponsors MorphoSys
  • Most Recent Events

    • 04 Dec 2018 Preliminary results of Cohort B ( data cut off date of June 18, 2018, n=13), presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Nov 2018 According to a MorphoSys AG media release, preliminary safety and efficacy results from this trial will be presented at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, taking place from December 1-4, 2018 in San Diego, California.
    • 20 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top